Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity

Author

Steve Jenkinson

Affiliation

Metrion Biosciences Ltd., Cambridge, UK

Journal

Genetic Engineering News. 2024 44:5, 48-50

Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity


View
Recommended Publications
Latest Publications
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.

The nucleobase guanine at the 3'-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity

Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'

View All
Meet our scientific leadership team pain experts
Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery
View All
Metrion is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram